LGND News Alert Ligand Pharmaceuticals Inc (LGND) 55.91 02/14/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 2:09 AM

Ligand Pharmaceuticals Inc (LGND) 55.91 $LGND

Ligand Pharmaceutical (LGND) Upgraded From Hold to Buy
at The Street - Wed Feb 11, 12:40PM CST
Ligand Pharmaceutical (LGND) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
LGND: 55.91 (-0.35)

Ligand Pharmaceuticals Had Strong 2014, Shares Barely Moved, Time To Act
Chris Katje - at Seeking Alpha - Tue Feb 10, 3:24PM CST

LGND: 55.91 (-0.35)

Ritter Pharmaceuticals elects Matthew W. Foehr to board
M2 - Tue Feb 10, 5:58AM CST
Pharmaceutical company Ritter Pharmaceuticals revealed on Monday the addition of Matthew W. Foehr to its board of directors to increase its directors to five.
LGND: 55.91 (-0.35)

Glaxo Submits Another Revolade Application in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:54PM CST
GlaxoSmithKline (GSK) announced that it has submitted another marketing application for Revolade in the EU.
AGN: 229.49 (+1.87), LGND: 55.91 (-0.35), GSK: 47.94 (+1.99)

Ligand Pharmaceuticals' (LGND) CEO John Higgins on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 12:57PM CST

LGND: 55.91 (-0.35)

Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 9:03AM CST
Ligand Pharmaceuticals (LGND) Posts In-Line Q4 Earnings
LGND: 55.91 (-0.35)

Ligand meets 4Q profit forecasts
Automated Insights - Mon Feb 09, 7:48AM CST
LA JOLLA, Calif. (AP) _ Ligand Pharmaceuticals Inc. (LGND) on Monday reported fourth-quarter profit of $7.1 million.
LGND: 55.91 (-0.35)

Ligand Pharmaceuticals EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 7:34AM CST

LGND: 55.91 (-0.35)

Ligand Reports Fourth Quarter and Full Year 2014 Financial Results
Business Wire - Mon Feb 09, 7:31AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and 12 months ended December 31, 2014, and provided an operating forecast and program updates.
LGND: 55.91 (-0.35)

Ritter Pharmaceuticals Names Matthew W. Foehr to Its Board of Directors
Business Wire - Mon Feb 09, 6:00AM CST
Ritter Pharmaceuticals, Inc., a privately held pharmaceutical company focused on gastrointestinal disorders, announces the appointment of Matthew W. Foehr to the Company's Board of Directors. Mr. Foehr is President and Chief Operating Officer of Ligand Pharmaceuticals (NASDAQ: LGND) and his appointment expands Ritter's Board membership to five Directors.
LGND: 55.91 (-0.35)

Ligand seeks additional indication for ITP drug Revolade from European Medicines Agency
M2 - Mon Feb 09, 5:54AM CST
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) disclosed on Friday the submission of data to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for eltrombopag (Revolade) seeking an additional indication for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
LGND: 55.91 (-0.35), GSK: 47.94 (+1.99)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Feb 08, 4:30PM CST

OAK: 57.07 (+1.39), ENSG: 40.91 (+0.06), HAS: 62.74 (+0.58), TE: 19.59 (-0.32), EXXI: 4.00 (+0.42), BWP: 16.95 (+0.63), GOLD: 78.29 (-0.31), L: 42.34 (+0.42), CYOU: 26.25 (+0.25), LGND: 55.91 (-0.35), MAS: 26.45 (+0.02), DO: 35.21 (+0.36), WEX: 104.53 (+0.47), NAT: 10.20 (+0.10), MPAA: 24.08 (-0.05), SOHU: 53.96 (+2.74), MCY: 53.93 (+0.05), CNA: 43.40 (+0.18)

Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:54AM CST
Ligand Pharmaceuticals (LGND) is scheduled to report fourth-quarter 2014 results on Feb 9, 2015 and holds a Zacks Rank #3 (Hold) with Earnings ESP of -4.17%.
ACT: 285.37 (+3.71), LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15), ARIA: 7.35 (+0.45)

Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade(R)
Business Wire - Fri Feb 06, 8:15AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner GlaxoSmithKline (GSK) plc reported the submission to the European Medicines Agency (EMA) of a variation to the Marketing Authorization for eltrombopag (Revolade(R)), seeking an additional indication for the treatment of pediatric patients (age 1 year and above) with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids or immunoglobulins.
LGND: 55.91 (-0.35), GSK: 47.94 (+1.99)

Ligand Signs License Agreement with Sermonix for Lasofoxifene
Business Wire - Tue Feb 03, 7:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the signing of a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the United States and additional territories. Under the terms of the agreement, Ligand has received an undisclosed initial payment, and is entitled to receive up to $45 million in potential regulatory and commercial milestone payments and tiered royalties of 6% to 10% on future net sales. Lasofoxifene is an estrogen partial agonist for the treatment of osteoporosis and other diseases.
LGND: 55.91 (-0.35)

Ligand elects Matthew W. Foehr as president
M2 - Tue Feb 03, 3:34AM CST
Biopharmaceutical company Ligand Pharmaceuticals (NasdaqGM:LGND) disclosed on Monday that it has appointed Matthew W. Foehr as its president, succeeding John Higgins who will continue to serve as chief executive officer.
LGND: 55.91 (-0.35)

New chief at Ligand Pharma
Seeking Alpha - at Seeking Alpha - Mon Feb 02, 4:09PM CST

LGND: 55.91 (-0.35)

Ligand Promotes Matthew W. Foehr to President
Business Wire - Mon Feb 02, 3:30PM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that Matthew W. Foehr has been promoted to President and Chief Operating Officer. Previously Mr. Foehr served as the Company's Executive Vice President and Chief Operating Officer. John Higgins, who had been serving as President and Chief Executive Officer, will continue to serve as the Company's Chief Executive Officer.
LGND: 55.91 (-0.35)

Earnings Peek: Stay With Ligand Pharmaceuticals For A Year Or Three
Clinically Sound Investor - at Seeking Alpha - Thu Jan 29, 3:27PM CST

LGND: 55.91 (-0.35)

Ligand to Present at BIO CEO and RBC Capital Markets Global Healthcare Conferences in February
Business Wire - Wed Jan 28, 7:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that company executives will be presenting at the following conferences:
LGND: 55.91 (-0.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...